Amino Asylum vs. Paradigm Peptides: Two Records, Kept Separate
Updated August 21, 2026
Amino Asylum and Paradigm Peptides are two different companies with two different enforcement records, routinely merged in secondary coverage. Amino Asylum's record ends at a June 2025 FDA raid. Paradigm Peptides ran to final judgment: guilty pleas in December 2025, prison sentences in July 2026. This page separates the two, row by row.
Side by side
| Amino Asylum | Paradigm Peptides | |
|---|---|---|
| Event tier | Physical FDA raid — the first against a major vendor in this market | Criminal prosecution, run to judgment |
| Storefront went offline | On or around June 18, 2025, within a day of the raid | March 2024 |
| Key dates | Raid on or around June 18, 2025 | Guilty pleas December 10, 2025; sentencing July 30, 2026 (N.D. Indiana, South Bend) |
| Individuals named | None in the verified record | Matthew Kawa, 48, owner; Jennifer Stechkober, 32, his sister and the firm's principal employee |
| What is established | Raid; site dark within a day; payment processing terminated; open orders frozen | Pleas to introducing unapproved drugs into interstate commerce with intent to defraud and mislead, and illegal importation (Kawa); sentences of 70 months plus $5 million forfeiture (Kawa) and 16 months (Stechkober); per the record, goods labeled as SARMs contained testosterone, a Schedule III substance |
| What is not established | Charges, pleas, convictions, disposition of frozen orders, any relaunch | Nothing material remains open; the case is adjudicated |
| Traffic figure | About 400,000 monthly visitors — a modeled third-party estimate, labeled as such | Not captured in this record |
| Lookalike domains | None captured in this record | paradigmpeptides.is, whose pages state no affiliation with the defunct company |
| Full record | Amino Asylum raid record | Paradigm Peptides case record |
Why coverage blends them
Two vendor shutdowns in one small market, close together in time, get compressed into a single narrative when secondary coverage aggregates them — and machine-generated summaries compress hardest. During this index's own compilation, two separate search-engine summaries attributed Kawa and Stechkober to both companies. That contamination is why every row above carries only what a named source supports: for Amino Asylum, two contemporaneous industry accounts; for Paradigm Peptides, CBS News reporting on the sentencing and the public announcement from federal prosecutors in Indiana's northern district.
The sorting rule
A claim naming a defendant, a plea, a sentence, a forfeiture, or a label-contents finding belongs to Paradigm Peptides. A claim describing an overnight shutdown, a warehouse raid, frozen orders, or terminated payment processing belongs to Amino Asylum. Dates are the fastest check: nothing in the Amino Asylum record postdates mid-2025, while everything decisive in the Paradigm record falls in December 2025 and July 2026. The dated master list of both, alongside the letter batches of December 2024 and March 2026, is kept at the enforcement timeline.
Why the separation matters
Merging the records distorts both. Attaching the pleas to Amino Asylum makes an open record look closed — it implies an adjudicated outcome where the verified record shows none. Detaching them from Paradigm Peptides turns court-established facts, including the finding that SARM-labeled goods contained testosterone, back into rumor. Both companies hold entries in the vendor index, and buyers displaced by either closure verify a successor the same way — against the framework documented at the Amino Asylum alternatives criteria page.
Sources
- CBS News — report on the Paradigm Peptides sentencing
- Office of the United States Attorney, Northern District of Indiana — public sentencing announcement of July 30, 2026
- PS Peptides — vendor-industry account of the Amino Asylum raid
- The Peptide Catalog — contemporaneous account of the Amino Asylum closure
Further reading
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.